SLC5A2 and COVID-19: Several studies have shown that drug therapy for the underlying disease is not associated with a substantial increase in the risk of COVID-19 severity, suggesting that metformin, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and beta blockers may improve the conversion [8, 9].